JP2003501488A - 骨髄抑制のための高投与量放射性核種錯体 - Google Patents

骨髄抑制のための高投与量放射性核種錯体

Info

Publication number
JP2003501488A
JP2003501488A JP2001502887A JP2001502887A JP2003501488A JP 2003501488 A JP2003501488 A JP 2003501488A JP 2001502887 A JP2001502887 A JP 2001502887A JP 2001502887 A JP2001502887 A JP 2001502887A JP 2003501488 A JP2003501488 A JP 2003501488A
Authority
JP
Japan
Prior art keywords
cancer
dose
bone marrow
bone
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001502887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501488A5 (US07119074-20061010-C00003.png
Inventor
ジー． エイブラムズ，ポール
エム． タタリック，ローレン
アール． トエルク，ケント
カイル ブライアン，ジェイムズ
ケー． ジョン，エリザベス
ディー． ハイラライズ，マーク
アール． フリッツバーグ，アラン
Original Assignee
ネオルックス コーポレイション
ジー． エイブラムズ，ポール
エム． タタリック，ローレン
アール． トエルク，ケント
カイル ブライアン，ジェイムズ
ケー． ジョン，エリザベス
ディー． ハイラライズ，マーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネオルックス コーポレイション, ジー． エイブラムズ，ポール, エム． タタリック，ローレン, アール． トエルク，ケント, カイル ブライアン，ジェイムズ, ケー． ジョン，エリザベス, ディー． ハイラライズ，マーク filed Critical ネオルックス コーポレイション
Publication of JP2003501488A publication Critical patent/JP2003501488A/ja
Publication of JP2003501488A5 publication Critical patent/JP2003501488A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001502887A 1999-06-11 2000-06-12 骨髄抑制のための高投与量放射性核種錯体 Pending JP2003501488A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60/139,065 1999-06-11
US13906599P 1999-07-11 1999-07-11
US14378099P 1999-07-13 1999-07-13
US60/143,780 1999-07-13
US14982199P 1999-08-19 1999-08-19
US60/149,821 1999-08-19
PCT/US2000/016052 WO2000076556A2 (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression

Publications (2)

Publication Number Publication Date
JP2003501488A true JP2003501488A (ja) 2003-01-14
JP2003501488A5 JP2003501488A5 (US07119074-20061010-C00003.png) 2007-08-02

Family

ID=27385279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001502887A Pending JP2003501488A (ja) 1999-06-11 2000-06-12 骨髄抑制のための高投与量放射性核種錯体

Country Status (6)

Country Link
US (6) US6767531B2 (US07119074-20061010-C00003.png)
EP (1) EP1191948A2 (US07119074-20061010-C00003.png)
JP (1) JP2003501488A (US07119074-20061010-C00003.png)
AU (1) AU5871000A (US07119074-20061010-C00003.png)
CA (1) CA2371728C (US07119074-20061010-C00003.png)
WO (1) WO2000076556A2 (US07119074-20061010-C00003.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016532652A (ja) * 2013-10-07 2016-10-20 アイソセラピューティクス グループ リミティド ライアビリティー カンパニーＩｓｏＴｈｅｒａｐｅｕｔｉｃｓ Ｇｒｏｕｐ ＬＬＣ 高純度治療用骨剤
JP2018515585A (ja) * 2015-05-25 2018-06-14 アイソセラピューティクス グループ リミティド ライアビリティー カンパニーＩｓｏＴｈｅｒａｐｅｕｔｉｃｓ Ｇｒｏｕｐ ＬＬＣ 放射性同位体用ｄｏｔｍｐキット製剤
JP2019501962A (ja) * 2015-12-07 2019-01-24 ジェネラル オンコロジー，インコーポレイテッド 患者における転移性癌の有効な治療のための組合せ

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501488A (ja) * 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
US7094885B2 (en) 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
WO2001091806A2 (en) * 2000-05-31 2001-12-06 Steven Mccullough Measurement of the therapeutic dose for bone marrow ablation therapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
AU2002249935A1 (en) * 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
US7045116B2 (en) 2001-12-13 2006-05-16 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
CA2509328A1 (en) * 2002-12-10 2004-06-24 University Of Miami Radioablation of hemolymphopoietic cell populations
US20070092440A1 (en) * 2003-05-09 2007-04-26 Edgar Braendle Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
WO2007126730A1 (en) * 2006-03-29 2007-11-08 Isotherapeautics Group Llc Radionuclide therapy for urinary bladder cancer
WO2008060663A2 (en) * 2006-04-14 2008-05-22 Thorenco, Llc Compact neutron generator for medical and commercial isotope production, fission product purification and controlled gamma reactions for direct electric power generation
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
TW200809194A (en) * 2006-05-04 2008-02-16 Wyeth Corp Determination of antibiotic concentration in bone
WO2008020033A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for the treatment of arthritis and pain
WO2009078924A2 (en) 2007-12-06 2009-06-25 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
US20100310465A1 (en) * 2008-01-23 2010-12-09 The Regents Of The University Of California Nano-devices having releasable seals for controlled release of molecules
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
WO2010078569A2 (en) * 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
US8702664B2 (en) * 2009-02-18 2014-04-22 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation
US20120207795A1 (en) * 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
CN103327986B (zh) 2010-07-22 2018-05-25 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法
AU2012249474A1 (en) 2011-04-28 2013-11-07 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
RU2599874C2 (ru) * 2014-10-13 2016-10-20 Михаил Сергеевич АНОСОВ Способ лечения хронического одонтогенного остеомиелита у наркозависимых больных
US11369700B2 (en) 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
RU2019139432A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Фармакокинетическая оптимизация бифункциональных хелатов и их применение
WO2018204872A2 (en) 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
EA202091396A1 (ru) 2017-12-07 2020-09-02 РИВЕН АйПи ХОЛДКО ЭлЭлСи Композиции и способы лечения метаболических состояний
WO2020092259A1 (en) * 2018-10-29 2020-05-07 Molecular Stethoscope, Inc. Characterization of bone marrow using cell-free messenger-rna
AR120059A1 (es) * 2019-06-12 2022-02-02 Reven Ip Holdco Llc Métodos y composiciones para mejorar resultados de pacientes con cáncer
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US470753A (en) * 1892-03-15 William grunow
US587451A (en) * 1897-08-03 James douglas o neill
US158393A (en) * 1875-01-05 Improvement in grates
US96393A (en) * 1869-11-02 Improved furniture-caster
US410436A (en) * 1889-09-03 packham
US589190A (en) * 1897-08-31 Apparatus for compressing air
US118508A (en) * 1871-08-29 Improvement in flour-bolts
US716818A (en) * 1901-04-13 1902-12-23 James A Ekin Criswell Machine for making matches.
US937333A (en) * 1909-06-26 1909-10-19 William H Shugart Rail-joint.
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3398097A (en) 1965-07-30 1968-08-20 Progressive Products Co Cleaning composition, and method of cleaning and sequestering metal ions
BE744394A (en) * 1970-01-14 1970-07-14 Elphiac Sa Zone refining process
US3726912A (en) 1970-07-02 1973-04-10 Dow Chemical Co Substituted alkanolamine chelating agents
US3989730A (en) 1972-06-15 1976-11-02 Research Corporation Bone-seeking technetium-99m complex
US3852414A (en) 1972-09-13 1974-12-03 New England Nuclear Corp Bone seeking technetium 99m stannous phosphate complex
US3965254A (en) 1973-05-23 1976-06-22 The Procter & Gamble Company Compositions for the treatment of calcific tumors
PH12898A (en) * 1973-05-23 1979-10-04 Procter & Gamble A composition for the treatment of calcific tumors
US3931396A (en) 1973-05-31 1976-01-06 Commissariat A L'energie Atomique Method of preparation of a composition having a base of 99m technetium for diagnosis by scintigraphy
US4058704A (en) 1974-12-27 1977-11-15 Taeo Kim Coilable and severable heating element
US4017596A (en) 1975-03-03 1977-04-12 Research Corporation Radiopharmaceutical chelates and method of external imaging
US3974268A (en) 1975-05-30 1976-08-10 Research Corporation Bone-seeking technetium-99m imidodiphosphonate complex
DE2543349C2 (de) 1975-09-29 1984-05-10 Henkel KGaA, 4000 Düsseldorf Preaparate zur herstellung von99m technetium-radiagnostica
US4075314A (en) 1976-04-29 1978-02-21 Mallinckrodt, Inc. Stannous pyrophosphate technetium-99m compositions
CA1078731A (en) 1976-12-16 1980-06-03 Charles E. Frosst And Co. Skeletal imaging kit utilizing triethylene tetramine hexa (methylene phosphonic acid)
US4399817A (en) 1981-06-30 1983-08-23 The Procter & Gamble Company Boron containing polyphosphonates for the treatment of calcific tumors
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4508625A (en) 1982-10-18 1985-04-02 Graham Marshall D Magnetic separation using chelated magnetic ions
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
DE3247054C1 (de) * 1982-12-20 1984-05-10 Goetze Ag, 5093 Burscheid Spritzpulver fuer die Herstellung verschleissfester Beschichtungen
SE8301395L (sv) 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4515767A (en) 1983-06-20 1985-05-07 The Dow Chemical Company Radioactive metals complexed with phosphonate derivatives of dicyclopentadienebis(methylamine)
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
US4560548A (en) 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
US4898724A (en) 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5066478A (en) 1984-06-04 1991-11-19 The Dow Chemical Company Radio labeled organic amine phosphonic acid complexes for the treatment of calcific tumors
AU563671B2 (en) 1984-06-04 1987-07-16 Dow Chemical Company, The Organic amine phosphonic acid complexes
US5059412A (en) 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US4606907A (en) 1984-07-02 1986-08-19 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of polyamidoamines
US4897254A (en) 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4639365A (en) 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4678687A (en) * 1984-10-31 1987-07-07 Xerox Corporation Thermal transfer printing sheets containing certain coating compositions thereof
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5556982A (en) * 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4752464A (en) 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
GB8518300D0 (en) 1985-07-19 1985-08-29 Amersham Int Plc Contrast agent
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3772785D1 (de) 1986-01-23 1991-10-17 Squibb & Sons Inc 1-substituiertes-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecan und analoga.
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
FR2614020B1 (fr) 1987-04-14 1989-07-28 Guerbet Sa Nouveaux ligands cycliques azotes, complexes metalliques formes par ces ligands, compositions de diagnostic contenant ces complexes et procede de preparation des ligands.
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
US5089249A (en) 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5202109A (en) 1988-06-10 1993-04-13 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US4937333A (en) 1989-08-04 1990-06-26 The Dow Chemical Company Method for purifying aminomethylenephosphonic acids for pharmaceutical use
US4882142A (en) 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US4976950A (en) 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
GB8903023D0 (en) 1989-02-10 1989-03-30 Parker David Chemical compounds
US5714467A (en) 1989-04-12 1998-02-03 The Rockefeller University Antibacterial and antimalarial hybrid peptides
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5064433A (en) * 1990-03-05 1991-11-12 Helix Medical, Inc. Voice prosthesis insertion assemblies
AU654951B2 (en) 1990-04-18 1994-12-01 Celltech Limited Tetra-aza macrocycles, processes for their preparation and their use in magnetic resonance imaging
ATE118788T1 (de) 1990-06-15 1995-03-15 Hoechst Schering Agrevo Gmbh Antifungisches polypeptid, verfahren zu seiner herstellung.
MC2260A1 (fr) * 1990-06-18 1993-04-26 Dow Chemical Co Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
KR0178956B1 (ko) 1990-08-20 1999-03-20 도리이 신이치로 항균성 페넴 에스테르 유도체
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5861430A (en) 1991-12-17 1999-01-19 Jasmine Fockerman Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents
US5919925A (en) 1992-01-22 1999-07-06 Pfizer Inc. 2-isocephem and oxacephem derivatives and use as antibacterial agents
ATE210464T1 (de) 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
PL173704B1 (pl) 1992-10-28 1998-04-30 Den Mat Corp Bezalkoholowa, przeciwbakteryjna kompozycja do higieny jamy ustnej
US5714604A (en) 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
AP568A (en) 1993-08-24 1996-11-25 Janssen Pharmaceutica Nv Antibacterial and antifouling oxathiazines and their oxides.
US5587451A (en) 1993-11-26 1996-12-24 The Dow Chemical Company Process for preparing polyazamacrocycles
FR2719481B1 (fr) 1994-05-05 1996-05-31 Oreal Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
WO1996012704A1 (fr) 1994-10-20 1996-05-02 Wakunaga Seiyaku Kabushiki Kaisha Nouveau derive de pyridone-carboxylate, ou sel de celui-ci, et antibacterien le contenant comme principe actif
DK0753001T3 (da) 1994-11-08 2000-05-08 Glaxo Wellcome Sa Antifungale sordaridinderivater
JPH09512831A (ja) 1994-11-17 1997-12-22 エフ・ホフマン−ラ ロシュ アーゲー ジベンズイミダゾール誘導体
CA2206315A1 (en) 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
US5773421A (en) 1995-01-10 1998-06-30 Abbott Laboratories Antifungal fusacandins
AU691743B2 (en) 1995-01-26 1998-05-21 Merck & Co., Inc. Novel antifungal cyclohexapeptides
CN1173898A (zh) 1995-02-08 1998-02-18 株式会社植物防御系统研究所 抗菌性萜烯化合物及其制造方法
JP3081773B2 (ja) 1995-03-31 2000-08-28 株式会社資生堂 Ｎ−アシルピペラジン誘導体及び抗菌剤、抗潰瘍剤
US5786325A (en) 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
KR100423590B1 (ko) 1995-08-02 2004-09-10 호따. 우리아치에씨아. 에세. 아. 항진균활성을갖는신규피리미돈유도체
EP0783502A1 (en) 1995-08-02 1997-07-16 J. URIACH & CIA. S.A. New carboxamides with antifungal activity
US5681430A (en) * 1995-08-23 1997-10-28 Thermo Fibertek Inc. Activity induction in papermaking
US5872249A (en) 1995-09-01 1999-02-16 Korea Institute Of Science And Technology 3-ammoniopropenyl cephalosporin compounds as antibacterial agents and process for preparing the same
WO1997009878A1 (en) 1995-09-15 1997-03-20 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
JPH11511467A (ja) 1995-09-15 1999-10-05 ファルマシア・アンド・アップジョン・カンパニー ５−アミドメチルα，β−飽和および不飽和３−アリールブチロラクトン抗菌剤
US5837726A (en) 1995-11-01 1998-11-17 Millennium Pharmaceuticals, Inc. Antifungal agents derived from aspergillus fumigatus
EP0781566B1 (en) 1995-12-26 2004-07-28 Toyo Boseki Kabushiki Kaisha Organic solvent-soluble mucopolysaccharide, antibacterial antithrombogenic composition and medical material
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP4058129B2 (ja) 1996-03-18 2008-03-05 株式会社資生堂 ピリジン誘導体及び抗潰瘍剤、抗菌剤
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
US5773696A (en) 1996-03-29 1998-06-30 Monsanto Company Antifungal polypeptide and methods for controlling plant pathogenic fungi
JP3693449B2 (ja) 1996-04-05 2005-09-07 三菱製紙株式会社 抗菌防黴剤およびそれを含有する繊維状物質
JP4150435B2 (ja) 1996-04-18 2008-09-17 株式会社資生堂 アルキレンジアミン誘導体及び抗潰瘍剤、抗菌剤
US5756725A (en) 1996-04-24 1998-05-26 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
US5917084A (en) 1996-07-03 1999-06-29 Millennium Pharmaceuticals, Inc. Antifungal agents
GB2315489A (en) 1996-07-17 1998-02-04 Merck & Co Inc Antifungal agent
US5837253A (en) 1996-07-26 1998-11-17 Agrogene Ltd. Preparation and use of Inula extracts as a fungicide for the control of plant diseases
US5908862A (en) 1996-07-31 1999-06-01 Abbot Laboratories Water-miscible esters of mono--and diglycerides having antibacterial activity and their use in inhibiting infection
UA51730C2 (uk) 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US5830855A (en) 1996-09-12 1998-11-03 Utah State University Lipodepsipeptides as antifungal and fungicidal agents
US5876738A (en) 1996-10-29 1999-03-02 Toagosei Co., Ltd. Antifungal phyllosilicate
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
JP4090087B2 (ja) 1997-04-04 2008-05-28 株式会社資生堂 ベンズアミド誘導体及び抗潰瘍剤、抗菌剤
US5863773A (en) 1997-09-30 1999-01-26 Abbott Laboratories Antifungal corynecandin
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
JP2003501488A (ja) * 1999-06-11 2003-01-14 ネオルックス コーポレイション 骨髄抑制のための高投与量放射性核種錯体
US7094885B2 (en) 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
AU2002249935A1 (en) * 2001-01-08 2002-08-19 Neorx Corporation Radioactively labelled conjugates of phosphonates
US7045116B2 (en) * 2001-12-13 2006-05-16 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6010029613; ＴＵＲＮＥＲ，Ｊ．Ｈ．　ｅｔ　ａｌ: '１５３Ｓｍ-ＥＤＴＭＰ　ａｎｄ　ｍｅｌｐｈａｌａｎ　ｃｈｅｍｏｒａｄｉｏｔｈｅｒａｐｙ　ｒｅｇｉｍｅｎ　ｆｏｒ　ｂｏｎｅ　ｍａｒｒｏｗ　ａｂｌａｔｉｏｎ　ｐｒｉｏｒ　ｔｏ　ｍａｒｒｏｗ　ｔｒａｎｓｐｌ' Ｎｕｃｌ　Ｍｅｄ　Ｃｏｍｍｕｎ Ｖｏｌ．１３，　Ｎｏ．５, 1992, ｐ．３２１-９ *
JPN6010029615; ＴＵＲＮＥＲ，Ｊ．Ｈ．　ｅｔ　ａｌ: 'Ｒａｄｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ　ｔｈｅｒａｐｙ　ｏｆ　５Ｔ３３　ｍｕｒｉｎｅ　ｍｙｅｌｏｍａ　ｂｙ　ｓｅｑｕｅｎｔｉａｌ　ｔｒｅａｔｍｅｎｔ　ｗｉｔｈ　ｓａｍａｒｉｕｍ-１５３　ｅｔｈｙｌｅｎ' Ｊ　Ｎａｔｌ　Ｃａｎｃｅｒ　Ｉｎｓｔ Ｖｏｌ．８５，　Ｎｏ．１８, 1993, ｐ．１５０８-１３ *
JPN6010029616; ＰＡＲＫＳ，Ｎ．Ｊ．　ｅｔ　ａｌ: 'Ｂｏｎｅ　ｍａｒｒｏｗ　ｔｒａｎｓｐｌａｎｔａｔｉｏｎ　ｉｎ　ｄｏｇｓ　ａｆｔｅｒ　ｒａｄｉｏ-ａｂｌａｔｉｏｎ　ｗｉｔｈ　ａ　ｎｅｗ　Ｈｏ-１６６　ａｍｉｎｏ　ｐｈｏｓｐｈｏｎｉｃ　ａｃｉｄ　ｂｏｎ' Ｂｌｏｏｄ Ｖｏｌ．８２，　Ｎｏ．１, 1993, ｐ．３１８-２５ *
JPN6010029618; Ｐｏｄｏｌｏｆｆ　Ｄ　Ａ　ｅｔ　ａｌ．: 'Ｕｐｄａｔｅ　ｏｎ　ｔｈｅ　Ｈｏ-１６６　ＤＯＴＭＰ　ｂｏｎｅ　ｍａｒｒｏｗ　ａｂｌａｔｉｏｎ　ｔｒｉａｌ　ａｔ　Ｕ．Ｔ．Ｍ．Ｄ．　ａｎｄｅｒｓｏｎ　ｃａｎｃｅｒ　ｃｅｎｔｅｒ' Ｊｏｕｒｎａｌ　ｏｆ　Ｎｕｃｌｅａｒ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．３７，　Ｎｏ．５, 1996, ｐ．２３４ *
JPN6010029620; ＢＡＹＯＵＴＨ，Ｊ．Ｅ．　ｅｔ　ａｌ: 'Ｐｈａｒｍａｃｏｋｉｎｅｔｉｃｓ，　ｄｏｓｉｍｅｔｒｙ　ａｎｄ　ｔｏｘｉｃｉｔｙ　ｏｆ　ｈｏｌｍｉｕｍ-１６６-ＤＯＴＭＰ　ｆｏｒ　ｂｏｎｅ　ｍａｒｒｏｗ　ａｂｌａｔｉｏｎ　ｉｎ　ｍｕｌｔｉｐｌｅ　ｍ' Ｊ　Ｎｕｃｌ　Ｍｅｄ Ｖｏｌ．３６，　Ｎｏ．５, 1995, ｐ．７３０-７ *
JPN6010029622; Ｔｏｆｅ　Ａ　Ｊ　ｅｔ　ａｌ．: 'Ａｎｔｉｏｘｉｄａｎｔ　ｓｔａｂｉｌｉｚａｔｉｏｎ　ｏｆ　ｂｏｎｅ　ａｇｅｎｔｓ' Ｒａｄｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ , 1979, ｐ．６３７-４４ *
JPN6010029623; Ｔｏｆｅ　Ａ　Ｊ　ｅｔ　ａｌ．: 'Ａｎｔｉｏｘｉｄａｎｔ　ｓｔａｂｉｌｉｚａｔｉｏｎ　ｏｆ　ｂｏｎｅ　ａｇｅｎｔｓ' Ａｍｅｒｉｃａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｒｏｅｎｔｇｅｎｏｌｏｇｙ Ｖｏｌ．１３２，　Ｎｏ．３, 1979, ｐ．４９３ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016532652A (ja) * 2013-10-07 2016-10-20 アイソセラピューティクス グループ リミティド ライアビリティー カンパニーＩｓｏＴｈｅｒａｐｅｕｔｉｃｓ Ｇｒｏｕｐ ＬＬＣ 高純度治療用骨剤
JP2019123731A (ja) * 2013-10-07 2019-07-25 アイソセラピューティクス グループ リミティド ライアビリティー カンパニーＩｓｏＴｈｅｒａｐｅｕｔｉｃｓ Ｇｒｏｕｐ ＬＬＣ 高純度治療用骨剤
JP7068222B2 (ja) 2013-10-07 2022-05-16 アイジーエル ファーマ，インコーポレイティド 高純度治療用骨剤
JP2018515585A (ja) * 2015-05-25 2018-06-14 アイソセラピューティクス グループ リミティド ライアビリティー カンパニーＩｓｏＴｈｅｒａｐｅｕｔｉｃｓ Ｇｒｏｕｐ ＬＬＣ 放射性同位体用ｄｏｔｍｐキット製剤
JP2021113207A (ja) * 2015-05-25 2021-08-05 アイジーエル ファーマ，インコーポレイティド 放射性同位体用ｄｏｔｍｐキット製剤
JP7305699B2 (ja) 2015-05-25 2023-07-10 アイジーエル ファーマ，インコーポレイティド 放射性同位体用ｄｏｔｍｐキット製剤
JP2019501962A (ja) * 2015-12-07 2019-01-24 ジェネラル オンコロジー，インコーポレイテッド 患者における転移性癌の有効な治療のための組合せ
US11154520B2 (en) 2015-12-07 2021-10-26 General Oncology, Inc. Combination therapy for metastatic cancer

Also Published As

Publication number Publication date
US7408046B2 (en) 2008-08-05
US20020176818A1 (en) 2002-11-28
US20090136419A1 (en) 2009-05-28
AU5871000A (en) 2001-01-02
US6767531B2 (en) 2004-07-27
US7097823B2 (en) 2006-08-29
CA2371728A1 (en) 2000-12-21
US20070053833A1 (en) 2007-03-08
US7378077B2 (en) 2008-05-27
US7070759B2 (en) 2006-07-04
WO2000076556A9 (en) 2001-11-08
EP1191948A2 (en) 2002-04-03
US20050238578A1 (en) 2005-10-27
US20050129667A1 (en) 2005-06-16
US7696331B2 (en) 2010-04-13
CA2371728C (en) 2009-06-02
US20050063905A1 (en) 2005-03-24
WO2000076556A3 (en) 2001-10-11
WO2000076556A2 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
US7070759B2 (en) High dose radionuclide complexes for bone marrow suppression
US7691985B2 (en) Skeletal-targeted radiation to treat bone-associated pathologies
US7385042B2 (en) Therapeutic and diagnostic compounds, compositions, and methods
AU625644B2 (en) Bone marrow suppressing agents
AU657641B2 (en) Macrocyclic aminophosphonic acid complexes, their preparation, formulations and use
US7045116B2 (en) Treatment of osteomyelitis with radiopharmaceuticals
US4976950A (en) Bone marrow suppressing agents
JPH04230224A (ja) 放射性医薬製剤、その投与方法及びその製造方法
JP2536883B2 (ja) 骨髄抑制剤
EP1438076B1 (en) Radiopharmaceutical agent for the treatment of early stage cancer
AU624283B2 (en) Organic amine phosphonic acid complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101221

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110408